HSIC
Henry Schein, Inc.
HSIC's fundamentals are mixed: free cash flow grew 39%, while its operating margin held steady at 5.2%. At 24x earnings, it's trading in line with its usual 22x. Analysts expect earnings growth.
HSIC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
HSIC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
HSIC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $86.14 | — |
| Cheap | 17x | $60.99 | -29% |
| Fair | 21x | $78.46 | -8.9% |
| Current | 24x | $86.14 | — |
| Expensive | 25x | $90.36 | +4.9% |
Historical ranges are pointers, not guarantees.
HSIC's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
HSIC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HSIC, with profitability holding steady.
HSIC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.82 | +59% |
| Q3 2026 | $3.65 | +15% |
| Q2 2026 | $3.43 | +10% |
| Q1 2026 | $3.31 | +3.1% |
| Q4 2025 | $3.27 | +7.2% |
| Q3 2025 | $3.17 | +30% |
| Q2 2025 | $3.11 | +15% |
| Q1 2025 | $3.21 | +8.1% |
| Q4 2024 | $3.05 | -3.5% |
HSIC's earnings per share have fallen from their peak: $3.65 over the past year, against $4.88 in early 2020.
HSIC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.5B | +4% |
| Q2 2026 | $3.5B | +6.7% |
| Q1 2026 | $3.4B | +6.3% |
| Q4 2025 | $3.4B | +7.7% |
| Q3 2025 | $3.3B | +5.2% |
| Q2 2025 | $3.2B | +3.3% |
| Q1 2025 | $3.2B | -0.1% |
| Q4 2024 | $3.2B | +5.8% |
HSIC's revenue has grown year over year for six quarters in a row: $3.5B last quarter, up 4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.6% | +0.6 points |
| Q2 2026 | 5% | +0.3 points |
| Q1 2026 | 5.4% | -0.1 points |
| Q4 2025 | 4.7% | -0.1 points |
| Q3 2025 | 4.9% | 0 points |
| Q2 2025 | 4.7% | -0.4 points |
| Q1 2025 | 5.5% | +0.8 points |
| Q4 2024 | 4.9% | +3.6 points |
HSIC's operating margin was 5.6% last quarter, up 0.6 points from the same quarter a year ago.
HSIC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $131M | -7.1% |
| Q2 2026 | $212M | +141% |
| Q1 2026 | -$122M | -2133% |
| Q4 2025 | $338M | +101% |
| Q3 2025 | $141M | +21% |
| Q2 2025 | $88M | -66% |
| Q1 2025 | $6M | -96% |
| Q4 2024 | $168M | +$239M |
HSIC generated $559M in free cash flow over the past year, up 39% from the year before.
HSIC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -1.9M shares |
| 1 year | -7% | -8.5M shares |
| 3 years | -14% | -18.9M shares |
| 5 years | -20% | -28.5M shares |
| Available history | -25% | -36.7M shares |
HSIC has 113M diluted shares, down 7% from a year ago, with $650M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $125M |
| Q2 2026 | $200M |
| Q1 2026 | $125M |
| Q4 2025 | $200M |
| Q3 2025 | $203M |
| Q2 2025 | $286M |
| Q1 2025 | $161M |
| Q4 2024 | $75M |
HSIC spent $650M buying back its own shares over the past year, down 10% from the year before.
HSIC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 3.1x | Elevated |
| Q3 2025 | 3.2x | Elevated |
| Q2 2025 | 3.1x | Elevated |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 2.7x | Moderate |
HSIC's net debt is about 3.2 years of its operating earnings (EBITDA), about the same as a year ago.
HSIC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.0 | Neutral |
| Stochastic | 50.0 | Neutral |
HSIC's weekly RSI is 55 (neutral) and its Stochastic is 50 (neutral).
HSIC PE vs Healthcare Sector
| Metric | HSIC | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 8.7% below |
| PE % | 73 | 29 | 44 pts above |
HSIC is trading at 24x earnings, in line with the Healthcare sector's median of 26x.
HSIC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.5 | 0.8% above |
| 20 week MA | $86.6 | 0.6% below |
| 50 week MA | $80.8 | 6.7% above |
| 100 week MA | $75.4 | 14% above |
| 200 week MA | $74.8 | 15% above |
HSIC's trend is mixed: it's above four of its five weekly moving averages, and 15% above its 200-week average.
HSIC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.6 | $65.8 | -1.1% |
| 2021 | $65.8 | $74.9 | +14% |
| 2022 | $74.9 | $80.6 | +7.6% |
| 2023 | $80.6 | $75.7 | -6.1% |
| 2024 | $75.7 | $70.4 | -7% |
| 2025 | $70.4 | $76.1 | +8.1% |
| 2026 YTD | $76.1 | $86.1 | +13% |
HSIC has finished lower in three of the last six years. It's up 13% so far in 2026.